News
BMS eyes another celmod filing in myeloma after phase 3 win
Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.
Thursday 15 October 2026
